Integrated codependent submissions for tumour-agnostic or pan-tumour cancer medicines

The MSAC Executive commissioned and endorsed these complementary documents in 2019, to provide context for the emerging area of testing biomarkers to help decide eligibility for cancer medicines.

Collection description

The aim of these documents is to inform evidence considerations for codependent pan tumour testing applications to MSAC and PBAC.  While the discussion paper focuses on a specific example, these documents aim to help applicants and assessment groups consider aspects which may be relevant to other applications in this area.

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Last updated:
Audience:
Everyone
Resource type:
Collection
Tags:
  • MSAC support